Emcure Acquires 26% Stake In Torrent Urja For ₹3.72 Cr

PUNE | June 2, 2025:  Emcure Pharmaceuticals Limited (NSE: EMCURE | BSE: 544210) has announced that it has acquired a 26% stake in Torrent Urja 37 Private Limited (TUPL) for an amount of ₹3.72 crore. The move is aimed at helping Emcure move into captive renewable energy sourcing to meet its power requirements in Gujarat.

Deal Details

• Target: Torrent Urja 37 Private Limited (TUPL), a subsidiary of Torrent Green Energy Pvt. Ltd. (TGEPL)
• Stake Acquired: 26% (on a fully diluted basis)
• Acquisition Cost: ₹3,71,87,740
• Mode of Payment: Cash
• Regulatory Approvals Required: None
• Transaction Type: Not a related-party transaction

Strategic Objective

TUPL is setting up an 11.27 MWp ground-mounted solar photovoltaic power generation facility in Gujarat. This will operate as a captive power project, enabling Emcure to draw electricity directly for its manufacturing units and operations in the region.

Emcure has signed two Power Transfer Agreements (PTAs), dated June 2, 2025, which allow it to procure electricity generated by TUPL for captive consumption under open access. However, it is subject to obtaining the necessary consents and permissions from regulatory authorities.

Business and Operational Impact

This acquisition supports Emcure’s growing focus on sustainability and cost-efficient energy procurement. The company aims to utilise self-sufficient energy and reduce its carbon footprint. While TUPL is still in its setup phase and has not started commercial operations, the power generated through this arrangement is expected to benefit Emcure’s facilities in Gujarat upon completion.

About TUPL

• Incorporated: January 20, 2025
• Registered Office: Ahmedabad, Gujarat
• Industry: Renewable Energy
• Authorized & Paid-up Capital: ₹5 lakh
• Turnover: Not yet applicable (operations not commenced)

About Emcure Pharmaceuticals

Emcure Pharmaceuticals is a leading Indian pharmaceutical company that manufactures and markets a broad range of pharmaceutical products across various therapy areas. The company is the 12th largest pharma company in India and has a presence in over 70 countries.

REF:https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_1462389_02062025082211_WEB.xml

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. Every effort is made to ensure the accuracy, relevance, and timeliness of the information provided. However, inadvertent errors or omissions may occasionally occur.

Should you have any concerns, queries, or wish to point out any discrepancies in our content, please write to us at content@hdfcsec.com. Your feedback is valuable and helps us maintain the highest standards of content integrity.

Please note that the information shared is intended solely for informational purposes and should not be construed as investment advice. Users are advised to consult their financial advisors before making any investment decisions.